- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT07553559
일차 의료에서 노인을 위한 인공지능 기반 진단 보조 도구 평가 (INTERLACE)
집단 지성과 모방 학습을 통한 노인 진단 우수성 향상
Older adults commonly experience diagnostic errors that may lead to direct harms and increased healthcare costs. Older adults are especially at risk because of higher rates of comorbidity burden, medical complexity, frailty, and cognitive impairment. An artificial intelligence (AI) clinical decision support system (CDSS) offer a promising approach to promote diagnostic excellence for older adults.
The purpose of this study is to assess the acceptability and feasibility of a new AI CDSS for older adults in primary care. The goal of this AI CDSS is to provide diagnostic support during primary care visits (i.e., help make timely and accurate diagnoses) and support communication amongst patients, doctors, and caregivers about the patient's health.
In this study, participants will use the AI CDSS in a primary care visit and review its suggestions for diagnoses and tests. Afterwards, they will complete a feedback survey and interview where they share their thoughts about and experience using the AI CDSS.
연구 개요
상태
정황
연구 유형
등록 (추정된)
단계
- 해당 없음
연락처 및 위치
연구 연락처
- 이름: Alyssa M Sliwa, BA
- 전화번호: 215-746-3080
- 이메일: alyssa.sliwa@pennmedicine.upenn.edu
연구 연락처 백업
- 이름: Nicholas Bishop, BA
- 이메일: nicholas.bishop@pennmedicine.upenn.edu
연구 장소
-
-
Pennsylvania
-
Philadephia, Pennsylvania, 미국, 19104
- University of Pennsylvania
-
연락하다:
- Clinical Research Coordinator
- 전화번호: 215-746-3080
- 이메일: alyssa.sliwa@pennmedicine.upenn.edu
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
Clinicians
- Work in the University of Pennsylvania Health System
- Work in a primary care setting (i.e., Internal Medicine, Geriatric Medicine, Family Medicine, and Penn Primary Care)
- Actively treat adult patients who are 65 years old or older
Patients
- 65 years of age or older
- Have an upcoming encounter with a participating primary care clinician
- Indicate a new or worsening health concern that they wish to discuss at the upcoming encounter
Caregivers
- 18 years old or older
- Accompanying the participating patient during the encounter with the AI CDSS
- Identified by the patient as a caregiver
Exclusion Criteria:
An individual who meets any of the following criteria will be excluded from participation in this study:
- Under the age of 18 years old
- Unable to provide informed consent in the opinion of the investigator
- Has a "Research Do Not Contact" status in the electronic health record
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 특수 증상
- 할당: 해당 없음
- 중재 모델: 단일 그룹 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: Use of INTERLACE tool in primary care visit
All participants will be asked to use INTERLACE in their primary care visit. The tool will be presented on an handheld electronic device and may be used by patients, caregivers, and primary clinicians at each visit. First, the patient will input their current symptoms into INTERLACE. Then, using these symptoms, latest vital signs, and the patient's medical history, INTERLACE will make suggestions for diagnoses and tests. Patients, caregivers, and clinicians can view and discuss these suggestions together to arrive at a potential diagnosis. |
INTERLACE is an artificial intelligence-based clinical decision support tool. It uses a patient's medical history, vital signs, and current symptoms to make suggestions for diagnoses and tests. These suggestions can be considered and discussed amongst patients, caregivers, and clinicians during primary care visits to help find a good diagnosis for the patient's symptoms. |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Feasibility of embedding the AI CDSS into a primary care visit
기간: From enrollment to the end of the study interview, up to two weeks
|
Participants will complete a Feasibility of Intervention Measure (FIM) via feedback survey following the primary care visit. Responses are measured on a 5-point Likert scale. |
From enrollment to the end of the study interview, up to two weeks
|
|
Feasibility of embedding the AI CDSS into a primary care visit
기간: From enrollment until the end of the study interview, up to two weeks
|
Feasibility will also be assessed through brief survey questions asking whether participants experienced any barriers to using INTERLACE, whether it was useful during the visit, and how long it was used (all measured on a 7-point Likert scale), as well as open-ended questions in a semi-structured interview. |
From enrollment until the end of the study interview, up to two weeks
|
|
Acceptability of embedding the AI CDSS into a primary care visit
기간: From enrollment until the end of the study interview, up to two weeks
|
Participants will complete the Acceptability of Intervention Measure (AIM) via feedback survey after the primary care visit. Responses to the AIM are measured on a 5-point Likert scale. |
From enrollment until the end of the study interview, up to two weeks
|
|
Acceptability of embedding the AI CDSS into a primary care visit
기간: From enrollment until the end of the study interview, up to two weeks
|
Participants will also complete a modified version of the Technology Acceptance model (TAM). Responses to the TAM are measured on a 7-point Likert scale. |
From enrollment until the end of the study interview, up to two weeks
|
|
Acceptability of embedding the AI CDSS into a primary care visit
기간: From enrollment until the end of the study interview, up to two weeks
|
Participants will complete a Net Promoter Score assessing the likelihood that they would recommend the AI CDSS to others at the end of the survey. This will be measured on a 10-point scale. |
From enrollment until the end of the study interview, up to two weeks
|
|
Acceptability of embedding the AI CDSS into a primary care visit
기간: From enrollment until the end of the study interview, up to two weeks
|
Acceptability will also be assessed through brief survey questions assessing whether INTERLACE caused distress (measured on a 7 point Likert scale), as well as open-ended questions in a semi-structured interview. |
From enrollment until the end of the study interview, up to two weeks
|
공동 작업자 및 조사자
협력자
수사관
- 수석 연구원: Gary E Weissman, MD, MSPH, University of Pennsylvania
연구 기록 날짜
연구 주요 날짜
연구 시작 (추정된)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
기타 연구 ID 번호
- 852952
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .